# Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease

> **NCT00252850** · PHASE1 · COMPLETED · sponsor: **Sangamo Therapeutics** · enrollment: 12 (—)

## Conditions studied

- Parkinson's Disease

## Interventions

- **GENETIC:** CERE-120: AAV2-NTN

## Key facts

- **NCT ID:** NCT00252850
- **Lead sponsor:** Sangamo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 12 (—)
- **Last updated:** 2022-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00252850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00252850, "Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00252850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*